Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.63 |
| ▸ | TLR2 | O60603 | 1/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.55 |
| ▸ | NMT2 | O60551 | 1/20 | 0.55 |
| ▸ | NMT1 | P30419 | 1/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.54 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.54 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9517290 | 0.94 | GLP1R (0.61) | GLP1RLPAR3LPAR1 | |
| SCHEMBL9441752 | 0.94 | GLP1R (0.61) | GLP1RLPAR3LPAR1 | |
| SCHEMBL22684529 | 0.92 | NOD1 (0.55) | SIRT6SIRT1TLR2GLP1RLPAR3 | |
| SCHEMBL6931475 | 0.92 | NOD1 (0.60) | GLP1RLPAR3LPAR1 | |
| SCHEMBL23519401 | 0.91 | SIRT6 (0.76) | SIRT6SIRT1TLR2GRIA1GLP1R | |
| SCHEMBL20542815 | 0.91 | SIRT6 (0.76) | SIRT6SIRT1TLR2GRIA1GLP1R | |
| SCHEMBL20543069 | 0.91 | SIRT6 (0.76) | SIRT6SIRT1TLR2GRIA1GLP1R | |
| SCHEMBL20542813 | 0.91 | SIRT6 (0.76) | SIRT6SIRT1TLR2GRIA1GLP1R | |
| SCHEMBL20543067 | 0.91 | SIRT6 (0.76) | SIRT6SIRT1TLR2GRIA1GLP1R | |
| SCHEMBL20542968 | 0.91 | SIRT6 (0.76) | SIRT6SIRT1TLR2GRIA1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177981-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3740212-A2 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | Merck Sharp & Dohme Corp. (US) | 2020-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177981-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | GPR119, INSR, IGF1R | SIRT6 1449/4885SIRT1 2338/4885TLR2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.